What is Bioxcel Therapeutics Inc's earnings per share (EPS)?

Bioxcel Therapeutics Inc (BTAI) reported diluted earnings per share of $-5.73 for fiscal year 2025. This represents a 75.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bioxcel Therapeutics Inc Financials

BTAI

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Bioxcel Therapeutics Inc (BTAI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BTAI FY2025 2026-04-22

BioXcel’s reported model is still cash-funded drug development, with external financing covering losses while reported revenue remains minimal.

From FY2024 to FY2025, operating cash burn eased from -$72.0M to -$57.6M, but that did not make the business self-funding. In FY2025, financing inflows of $56.5M nearly offset the -$57.6M operating cash drain, showing that capital raising rather than reported sales is still what keeps liquidity in place.

The narrower loss since FY2023 is mainly a cost-compression story: combined R&D and SG&A fell from $167.7M to $50.7M by FY2025. That means the improvement in earnings reflects a smaller spending base more than a revenue engine gaining scale.

FY2025 ended with current assets of $44.7M against current liabilities of $53.9M, so near-term obligations now exceed liquid resources. With negative equity still on the balance sheet, debt and fresh capital are carrying an enterprise that has not yet turned development spending into durable operating cash flow.

Financial Health Signals

Financial Profile 15/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Bioxcel Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Bioxcel Therapeutics Inc has an operating margin of -7860.0%, meaning the company retains $-7860 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2967.6% the prior year.

Growth

Bioxcel Therapeutics Inc's revenue declined 71.7% year-over-year, from $2.3M to $642K. This contraction results in a growth score of 0/100.

Leverage

Bioxcel Therapeutics Inc carries a low D/E ratio of -0.89, meaning only $-0.89 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Bioxcel Therapeutics Inc's current ratio of 0.83 is below the typical benchmark, resulting in a score of 11/100. However, the company holds substantial cash reserves (53% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Cash Flow

While Bioxcel Therapeutics Inc generated -$57.6M in operating cash flow, capex of $0 consumed most of it, leaving -$57.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

3/9

Bioxcel Therapeutics Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.82x

For every $1 of reported earnings, Bioxcel Therapeutics Inc generates $0.82 in operating cash flow (-$57.6M OCF vs -$69.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-3.3x

Bioxcel Therapeutics Inc earns $-3.3 in operating income for every $1 of interest expense (-$50.5M vs $15.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$642K

YoY-71.7%

Bioxcel Therapeutics Inc generated $642K in revenue in fiscal year 2025. This represents a decrease of 71.7% from the prior year.

EBITDA

-$50.2M

YoY+25.1%

Bioxcel Therapeutics Inc's EBITDA was -$50.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.1% from the prior year.

Net Income

-$69.9M

YoY-17.3%

Bioxcel Therapeutics Inc reported -$69.9M in net income in fiscal year 2025. This represents a decrease of 17.3% from the prior year.

EPS (Diluted)

$-5.73

YoY+75.6%

Bioxcel Therapeutics Inc earned $-5.73 per diluted share (EPS) in fiscal year 2025. This represents an increase of 75.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$57.6M

YoY+20.0%

Bioxcel Therapeutics Inc generated -$57.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 20.0% from the prior year.

Cash & Debt

$28.4M

YoY-4.8%

5Y CAGR-33.2%

Bioxcel Therapeutics Inc held $28.4M in cash against $84.7M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

22M

YoY+619.8%

5Y CAGR-1.8%

Bioxcel Therapeutics Inc had 22M shares outstanding in fiscal year 2025. This represents an increase of 619.8% from the prior year.

Margins & Returns

Gross Margin

74.5%

YoY+69.0pp

Bioxcel Therapeutics Inc's gross margin was 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 69.0 percentage points from the prior year.

Operating Margin

-7860.0%

YoY-4892.4pp

Bioxcel Therapeutics Inc's operating margin was -7860.0% in fiscal year 2025, reflecting core business profitability. This is down 4892.4 percentage points from the prior year.

Net Margin

-10887.4%

YoY-8257.2pp

Bioxcel Therapeutics Inc's net profit margin was -10887.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 8257.2 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$30.3M

YoY-0.6%

5Y CAGR-12.2%

Bioxcel Therapeutics Inc invested $30.3M in research and development in fiscal year 2025. This represents a decrease of 0.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

Bioxcel Therapeutics Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure.

BTAI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$642K-71.7%	$2.3M+64.2%	$1.4M+268.0%	$375K	N/A	N/A
Cost of Revenue	$164K-92.3%	$2.1M+70.1%	$1.3M+6200.0%	$20K	N/A	N/A
Gross Profit	$478K+288.6%	$123K+2.5%	$120K-66.2%	$355K	N/A	N/A
R&D Expenses	$30.3M-0.6%	$30.4M-63.9%	$84.3M-7.6%	$91.2M+73.1%	$52.7M-9.1%	$58.0M
SG&A Expenses	$20.5M-40.6%	$34.5M-58.6%	$83.4M+21.3%	$68.8M+26.8%	$54.2M+123.1%	$24.3M
Operating Income	-$50.5M+25.0%	-$67.2M+60.9%	-$171.8M-7.6%	-$159.6M-49.3%	-$106.9M-29.9%	-$82.3M
Interest Expense	$15.3M+4.6%	$14.7M+10.1%	$13.3M+62.1%	$8.2M+20432.5%	$40K+48.1%	$27K
Income Tax	$0	$0	$0	N/A	N/A	N/A
Net Income	-$69.9M-17.3%	-$59.6M+66.7%	-$179.1M-8.0%	-$165.8M-55.0%	-$106.9M-30.1%	-$82.2M
EPS (Diluted)	$-5.73+75.6%	$-23.51+76.1%	$-98.33-1561.0%	$-5.92-46.2%	$-4.05-6.9%	$-3.79

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$256K+161.2%	$98K-18.3%	$120K-28.6%	$168K-54.1%	$366K+71.0%	$214K-80.6%	$1.1M+89.7%	$582K
Cost of Revenue	$32K+190.9%	$11K-89.7%	$107K+664.3%	$14K-98.3%	$831K-29.0%	$1.2M+1787.1%	$62K-22.5%	$80K
Gross Profit	$224K+157.5%	$87K+569.2%	$13K-91.6%	$154K+133.1%	-$465K+51.4%	-$956K-191.7%	$1.0M+107.6%	$502K
R&D Expenses	$6.7M-23.3%	$8.7M-14.8%	$10.3M+125.2%	$4.6M-22.8%	$5.9M+15.7%	$5.1M-36.5%	$8.0M-29.6%	$11.4M
SG&A Expenses	$3.8M-29.3%	$5.4M-4.1%	$5.6M-1.6%	$5.7M+39.2%	$4.1M-46.7%	$7.7M-18.7%	$9.4M-28.8%	$13.3M
Operating Income	-$10.3M+27.7%	-$14.2M+10.2%	-$15.9M-57.0%	-$10.1M+3.8%	-$10.5M+31.4%	-$15.3M+11.6%	-$17.3M+28.4%	-$24.2M
Interest Expense	$3.9M-0.1%	$3.9M+2.7%	$3.8M+5.1%	$3.6M-3.3%	$3.8M+2.3%	$3.7M+2.2%	$3.6M-0.1%	$3.6M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$12.5M+59.4%	-$30.9M-61.1%	-$19.2M-164.5%	-$7.3M+33.2%	-$10.9M+20.4%	-$13.7M-64.5%	-$8.3M+69.0%	-$26.8M
EPS (Diluted)	N/A	$-2.18+11.0%	$-2.45-63.3%	$-1.50	N/A	$-5.15-56.1%	$-3.30+76.2%	$-13.89

BTAI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$44.9M+17.2%	$38.3M-48.0%	$73.7M-64.2%	$205.9M-14.0%	$239.4M+8.9%	$219.9M
Current Assets	$44.7M+19.5%	$37.4M-48.2%	$72.1M-64.4%	$202.9M-14.3%	$236.8M+9.1%	$217.1M
Cash & Equivalents	$28.4M-4.8%	$29.9M-54.2%	$65.2M-66.3%	$193.7M-16.8%	$233.0M+9.3%	$213.1M
Inventory	$722K+6.3%	$679K-65.9%	$2.0M+0.3%	$2.0M	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$140.4M+6.8%	$131.4M+0.9%	$130.2M+0.9%	$129.1M+626.3%	$17.8M+34.2%	$13.2M
Current Liabilities	$53.9M+142.5%	$22.2M-18.5%	$27.3M-17.1%	$32.9M+97.4%	$16.7M+40.7%	$11.8M
Long-Term Debt	$84.7M-17.4%	$102.5M+1.9%	$100.6M+8.1%	$93.1M	N/A	N/A
Total Equity	-$95.5M-2.5%	-$93.1M-64.8%	-$56.5M-173.6%	$76.8M-65.4%	$221.7M+7.2%	$206.7M
Retained Earnings	-$720.1M-10.8%	-$650.2M-10.1%	-$590.6M-43.5%	-$411.5M-67.4%	-$245.8M-77.0%	-$138.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$44.9M+0.3%	$44.8M+73.7%	$25.8M-33.1%	$38.6M+0.6%	$38.3M-21.6%	$48.9M-25.3%	$65.4M-20.5%	$82.3M
Current Assets	$44.7M+0.6%	$44.4M+75.9%	$25.2M-33.2%	$37.8M+1.0%	$37.4M-21.8%	$47.8M-25.5%	$64.2M-20.7%	$80.9M
Cash & Equivalents	$28.4M-21.5%	$36.2M+107.5%	$17.4M-43.8%	$31.0M+3.9%	$29.9M-26.1%	$40.4M-28.2%	$56.3M-24.1%	$74.1M
Inventory	$722K+57.3%	$459K-9.3%	$506K-21.2%	$642K-5.4%	$679K-55.5%	$1.5M-43.1%	$2.7M+9.9%	$2.4M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$140.4M+5.0%	$133.7M+0.2%	$133.5M+3.7%	$128.7M-2.1%	$131.4M-2.3%	$134.5M-3.7%	$139.7M-9.7%	$154.7M
Current Liabilities	$53.9M+42.6%	$37.8M+13.3%	$33.4M+30.7%	$25.5M+14.9%	$22.2M-13.0%	$25.6M-6.3%	$27.3M-13.3%	$31.5M
Long-Term Debt	$84.7M-8.3%	$92.3M-5.3%	$97.5M-2.5%	$99.9M-2.5%	$102.5M-1.8%	$104.4M+1.4%	$103.0M+1.4%	$101.6M
Total Equity	-$95.5M-7.4%	-$88.9M+17.4%	-$107.7M-19.4%	-$90.2M+3.1%	-$93.1M-8.7%	-$85.6M-15.3%	-$74.3M-2.7%	-$72.4M
Retained Earnings	-$720.1M-1.8%	-$707.5M-4.6%	-$676.6M-2.9%	-$657.5M-1.1%	-$650.2M-1.7%	-$639.3M-2.2%	-$625.7M-1.3%	-$617.4M

BTAI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$57.6M+20.0%	-$72.0M+53.5%	-$155.0M-14.5%	-$135.3M-64.7%	-$82.2M-23.8%	-$66.3M
Capital Expenditures	$0	$0-100.0%	$20K-85.6%	$139K-68.8%	$445K+40.8%	$316K
Free Cash Flow	-$57.6M+20.0%	-$72.0M+53.5%	-$155.0M-14.4%	-$135.5M-64.0%	-$82.6M-23.9%	-$66.7M
Investing Cash Flow	$0	$0+100.0%	-$20K+85.6%	-$139K+68.8%	-$445K-40.8%	-$316K
Financing Cash Flow	$56.5M+54.2%	$36.7M+38.2%	$26.5M-72.4%	$96.2M-6.1%	$102.4M-58.6%	$247.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$9.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$14.2M+24.4%	-$18.8M-49.4%	-$12.6M-4.4%	-$12.0M+18.7%	-$14.8M+9.4%	-$16.3M+29.5%	-$23.2M-30.9%	-$17.7M
Capital Expenditures	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Free Cash Flow	-$14.2M+24.4%	-$18.8M	N/A	N/A	-$14.8M+9.4%	-$16.3M	N/A	N/A
Investing Cash Flow	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Financing Cash Flow	$5.6M-85.0%	$37.5M+27295.6%	$137K-99.0%	$13.2M+208.7%	$4.3M+841.9%	$454K-91.4%	$5.3M-80.1%	$26.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BTAI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	74.5%+69.0pp	5.4%-3.3pp	8.7%-86.0pp	94.7%	N/A	N/A
Operating Margin	-7860.0%-4892.4pp	-2967.6%+9480.4pp	-12448.0%+30124.0pp	-42572.0%	N/A	N/A
Net Margin	-10887.4%-8257.2pp	-2630.1%+10344.7pp	-12974.9%+31227.0pp	-44201.9%	N/A	N/A
Return on Equity	N/A	N/A	N/A	-215.9%-167.7pp	-48.2%-8.5pp	-39.8%
Return on Assets	-155.6%-0.2pp	-155.5%+87.5pp	-242.9%-162.4pp	-80.5%-35.9pp	-44.7%-7.3pp	-37.4%
Current Ratio	0.83-0.9	1.68-1.0	2.65-3.5	6.17-8.0	14.21-4.1	18.33
Debt-to-Equity	-0.89+0.2	-1.10+0.7	-1.78-3.0	1.21+1.1	0.08+0.0	0.06
FCF Margin	-8974.3%-5795.7pp	-3178.6%+8055.2pp	-11233.8%+24894.2pp	-36128.0%	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	87.5%-1.3pp	88.8%+78.0pp	10.8%-80.8pp	91.7%+218.7pp	-127.0%+319.7pp	-446.7%-541.1pp	94.4%+8.1pp	86.3%
Operating Margin	-4016.4%+10502.0pp	-14518.4%-1308.4pp	-13210.0%-7198.7pp	-6011.3%-3144.4pp	-2866.9%+4279.3pp	-7146.3%-5579.6pp	-1566.7%+2585.1pp	-4151.7%
Net Margin	-4900.4%+26641.5pp	-31541.8%-15552.7pp	-15989.2%-11671.3pp	-4317.9%-1350.9pp	-2966.9%+3411.6pp	-6378.5%-5626.8pp	-751.7%+3851.5pp	-4603.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-27.9%+41.1pp	-69.0%+5.4pp	-74.4%-55.6pp	-18.8%+9.5pp	-28.3%-0.4pp	-27.9%-15.2pp	-12.7%+19.9pp	-32.5%
Current Ratio	0.83-0.3	1.17+0.4	0.76-0.7	1.48-0.2	1.68-0.2	1.87-0.5	2.35-0.2	2.57
Debt-to-Equity	-0.89+0.2	-1.04-0.1	-0.91+0.2	-1.110.0	-1.10+0.1	-1.22+0.2	-1.39+0.0	-1.40
FCF Margin	-5550.8%+13619.6pp	-19170.4%	N/A	N/A	-4046.2%+3588.4pp	-7634.6%	N/A	N/A

Note: Shareholder equity is negative (-$95.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.83), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

MAIA Biotechnology Inc. MAIA

$80.1M

JUPITER NEUROSCIENCES, INC. JUNS

$16.9M

Pds Biotechnology Corporation PDSB

$74.8M

Vtv Therapeutics VTVT

$151.6M

Actinium Pharmac ATNM

$47.7M

Frequently Asked Questions

What is Bioxcel Therapeutics Inc's annual revenue?

Bioxcel Therapeutics Inc (BTAI) reported $642K in total revenue for fiscal year 2025. This represents a -71.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bioxcel Therapeutics Inc's revenue growing?

Bioxcel Therapeutics Inc (BTAI) revenue declined by 71.7% year-over-year, from $2.3M to $642K in fiscal year 2025.

Is Bioxcel Therapeutics Inc profitable?

No, Bioxcel Therapeutics Inc (BTAI) reported a net income of -$69.9M in fiscal year 2025, with a net profit margin of -10887.4%.

What is Bioxcel Therapeutics Inc's EBITDA?

Bioxcel Therapeutics Inc (BTAI) had EBITDA of -$50.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Bioxcel Therapeutics Inc have?

As of fiscal year 2025, Bioxcel Therapeutics Inc (BTAI) had $28.4M in cash and equivalents against $84.7M in long-term debt.

What is Bioxcel Therapeutics Inc's gross margin?

Bioxcel Therapeutics Inc (BTAI) had a gross margin of 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bioxcel Therapeutics Inc's operating margin?

Bioxcel Therapeutics Inc (BTAI) had an operating margin of -7860.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bioxcel Therapeutics Inc's net profit margin?

Bioxcel Therapeutics Inc (BTAI) had a net profit margin of -10887.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bioxcel Therapeutics Inc's free cash flow?

Bioxcel Therapeutics Inc (BTAI) generated -$57.6M in free cash flow during fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bioxcel Therapeutics Inc's operating cash flow?

Bioxcel Therapeutics Inc (BTAI) generated -$57.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bioxcel Therapeutics Inc's total assets?

Bioxcel Therapeutics Inc (BTAI) had $44.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bioxcel Therapeutics Inc's capital expenditures?

Bioxcel Therapeutics Inc (BTAI) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bioxcel Therapeutics Inc spend on research and development?

Bioxcel Therapeutics Inc (BTAI) invested $30.3M in research and development during fiscal year 2025.

How many shares does Bioxcel Therapeutics Inc have outstanding?

Bioxcel Therapeutics Inc (BTAI) had 22M shares outstanding as of fiscal year 2025.

What is Bioxcel Therapeutics Inc's current ratio?

Bioxcel Therapeutics Inc (BTAI) had a current ratio of 0.83 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Bioxcel Therapeutics Inc's debt-to-equity ratio?

Bioxcel Therapeutics Inc (BTAI) had a debt-to-equity ratio of -0.89 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bioxcel Therapeutics Inc's return on assets (ROA)?

Bioxcel Therapeutics Inc (BTAI) had a return on assets of -155.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bioxcel Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Bioxcel Therapeutics Inc (BTAI) had $28.4M in cash against an annual operating cash burn of $57.6M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Bioxcel Therapeutics Inc's debt-to-equity ratio negative or unusual?

Bioxcel Therapeutics Inc (BTAI) has negative shareholder equity of -$95.5M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Bioxcel Therapeutics Inc's Piotroski F-Score?

Bioxcel Therapeutics Inc (BTAI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bioxcel Therapeutics Inc's earnings high quality?

Bioxcel Therapeutics Inc (BTAI) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bioxcel Therapeutics Inc cover its interest payments?

Bioxcel Therapeutics Inc (BTAI) has an interest coverage ratio of -3.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bioxcel Therapeutics Inc?

Bioxcel Therapeutics Inc (BTAI) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.